Biogen Idec Inc (BIIB) 337.60 $BIIB
Jim Cramer's 'Mad Money' Recap: Unconventional Wisdom
at The Street - Wed Jul 23, 7:05PM CDT
Should investors settle for average results? Absolutely not, Cramer says.
3 Key Takeaways from Biogen Idec Inc Stock's Earnings Annihilation
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Wed Jul 23, 5:19PM CDT
Biogen Idec is absolutely humiliating Wall Street analysts with truly impressive second quarter results. The big biotech saw monumental gains as revenue soared 40% and adjusted earnings grew 52% year over year. Importantly, this isn't a one time...
Nasdaq stocks posting largest percentage increases
AP - Wed Jul 23, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Avanir to Conduct Phase II Study on AVP-786 for Depression - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 4:50PM CDT
Avanir Pharmaceuticals, Inc.'s (AVNR) AVP-786 has been accepted by the FDA for a phase II study for the adjunctive treatment of major depressive disorder (MDD).
Watch for Biogen Idec to Potentially Pullback After Gaining 11.17% Yesterday
Comtex SmarTrend(R) - Wed Jul 23, 3:38PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $331.00 to a high of $343.59. Yesterday, the shares gained 11.2%, which took the trading range above the 3-day high of $308.68 on volume of 4.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Delta and Apple are big market movers
AP - Wed Jul 23, 3:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 11.17%
Comtex SmarTrend(R) - Wed Jul 23, 3:38PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $331.00 to a high of $343.59. Yesterday, the shares gained 11.2%, which took the trading range above the 3-day high of $308.68 on volume of 4.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Stock's Tecfidera Embarrasses Wall Street
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 23, 3:31PM CDT
Source: Biogen Idec It's hard to imagine that Biogen Idec believed Tecfidera would become one of the top selling multiple sclerosis drugs just one year after its launch, but that's exactly what happened. Tecfidera was the third oral MS drug to...
S&P 500 Posts New High; Biotechs, Airlines, Builders Up
at Investor's Business Daily - Wed Jul 23, 3:16PM CDT
Stocks finished on a confident note Wednesday, posting modest gains and refusing to give much back throughout the session. The Nasdaq led the indexes with a 0.4% pop, while the S&P 500 added 0.2%, good enough for a new high. The Dow Jones industrial...
IPO Stock Watch: Biotechs Are Half Of July Calendar
at Investor's Business Daily - Wed Jul 23, 3:07PM CDT
July could see 19 biotechs go public and currently represent 50% of the 34 IPOs scheduled for the next two weeks, according to Renaissance Capital. It's also a sharp spike from the 38 biotech initial public offerings in the first half of the year....
S&P 500 Flirts With High; Breadth Missing On Nasdaq
at Investor's Business Daily - Wed Jul 23, 2:14PM CDT
Stocks kept to a tight trading range Wednesday as the market headed into its final hour of action. The Nasdaq was up 0.4% and the S&P 500 0.2%, but the Dow Jones industrial average eased 0.1%. Volume was running above the previous session's pace on...
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 1:15PM CDT
AbbVie's (ABBV) agreement to acquire Shire remained the top story in the biotech sector last week.
Why Biogen Idec Inc. Stock Popped Today
Brian Pacampara, The Motley Fool - Motley Fool - Wed Jul 23, 1:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotech giant Biogen Idec surged 11%...
5 Novartis Drugs You Need To Know About
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 23, 1:00PM CDT
Novartis is one of the planet's top drug manufacturers and its 3% dividend yield makes it a staple in dividend investor portfolios. However, Novartis is facing significant threats from competitors Biogen Idec and Regeneron which could crimp...
S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade
at Investor's Business Daily - Wed Jul 23, 12:29PM CDT
Stocks added gains Wednesday afternoon as the S&P 500 tried to hold on to a new high. The Nasdaq rose 0.3%, while the S&P 500 tacked on 0.1%. The Dow Jones industrial average diverged, slipping 0.2%. Volume in the stock market today was running...
Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 12:20PM CDT
Biogen (BIIB) upped its earnings and revenue guidance significantly on the strong performance of Tecfidera and the AIFA agreement.
Apple, Microsoft Lead Nasdaq Higher; Dow Falters
at Investor's Business Daily - Wed Jul 23, 10:56AM CDT
Led by Apple (AAPL) and Microsoft (MSFT), the Nasdaq climbed Wednesday, with upside volume perking up for a second straight day. The S&P 500 was trading at a new high, approaching 2000. The Nasdaq rose 0.5%, the S&P 500 gained 0.3% and the Dow Jones...
Video: Biogen Trounces Q2 Estimates On Tecfidera
at Investor's Business Daily - Wed Jul 23, 10:56AM CDT
Big-cap biotech Biogen Idec (BIIB) soundly beat analysts' Q2 expectations and substantially raised its guidance early Wednesday, sending shares up more than 11% in midday trading in the stock market today to near 338, a four-month high. Biogen's Q2...
PLEGRIDY(TM) (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis
Business Wire - Wed Jul 23, 10:41AM CDT
--- Initial Country Launches Expected to Begin in the Coming Weeks -
Jim Cramer's 'Mad Money' Recap: Unconventional Wisdom
at The Street - Wed Jul 23, 7:05PM CDT
Should investors settle for average results? Absolutely not, Cramer says.
3 Key Takeaways from Biogen Idec Inc Stock's Earnings Annihilation
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Wed Jul 23, 5:19PM CDT
Biogen Idec is absolutely humiliating Wall Street analysts with truly impressive second quarter results. The big biotech saw monumental gains as revenue soared 40% and adjusted earnings grew 52% year over year. Importantly, this isn't a one time...
Nasdaq stocks posting largest percentage increases
AP - Wed Jul 23, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Avanir to Conduct Phase II Study on AVP-786 for Depression - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 4:50PM CDT
Avanir Pharmaceuticals, Inc.'s (AVNR) AVP-786 has been accepted by the FDA for a phase II study for the adjunctive treatment of major depressive disorder (MDD).
Watch for Biogen Idec to Potentially Pullback After Gaining 11.17% Yesterday
Comtex SmarTrend(R) - Wed Jul 23, 3:38PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $331.00 to a high of $343.59. Yesterday, the shares gained 11.2%, which took the trading range above the 3-day high of $308.68 on volume of 4.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Delta and Apple are big market movers
AP - Wed Jul 23, 3:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 11.17%
Comtex SmarTrend(R) - Wed Jul 23, 3:38PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $331.00 to a high of $343.59. Yesterday, the shares gained 11.2%, which took the trading range above the 3-day high of $308.68 on volume of 4.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Stock's Tecfidera Embarrasses Wall Street
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 23, 3:31PM CDT
Source: Biogen Idec It's hard to imagine that Biogen Idec believed Tecfidera would become one of the top selling multiple sclerosis drugs just one year after its launch, but that's exactly what happened. Tecfidera was the third oral MS drug to...
S&P 500 Posts New High; Biotechs, Airlines, Builders Up
at Investor's Business Daily - Wed Jul 23, 3:16PM CDT
Stocks finished on a confident note Wednesday, posting modest gains and refusing to give much back throughout the session. The Nasdaq led the indexes with a 0.4% pop, while the S&P 500 added 0.2%, good enough for a new high. The Dow Jones industrial...
IPO Stock Watch: Biotechs Are Half Of July Calendar
at Investor's Business Daily - Wed Jul 23, 3:07PM CDT
July could see 19 biotechs go public and currently represent 50% of the 34 IPOs scheduled for the next two weeks, according to Renaissance Capital. It's also a sharp spike from the 38 biotech initial public offerings in the first half of the year....
S&P 500 Flirts With High; Breadth Missing On Nasdaq
at Investor's Business Daily - Wed Jul 23, 2:14PM CDT
Stocks kept to a tight trading range Wednesday as the market headed into its final hour of action. The Nasdaq was up 0.4% and the S&P 500 0.2%, but the Dow Jones industrial average eased 0.1%. Volume was running above the previous session's pace on...
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 1:15PM CDT
AbbVie's (ABBV) agreement to acquire Shire remained the top story in the biotech sector last week.
Why Biogen Idec Inc. Stock Popped Today
Brian Pacampara, The Motley Fool - Motley Fool - Wed Jul 23, 1:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotech giant Biogen Idec surged 11%...
5 Novartis Drugs You Need To Know About
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 23, 1:00PM CDT
Novartis is one of the planet's top drug manufacturers and its 3% dividend yield makes it a staple in dividend investor portfolios. However, Novartis is facing significant threats from competitors Biogen Idec and Regeneron which could crimp...
S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade
at Investor's Business Daily - Wed Jul 23, 12:29PM CDT
Stocks added gains Wednesday afternoon as the S&P 500 tried to hold on to a new high. The Nasdaq rose 0.3%, while the S&P 500 tacked on 0.1%. The Dow Jones industrial average diverged, slipping 0.2%. Volume in the stock market today was running...
Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 12:20PM CDT
Biogen (BIIB) upped its earnings and revenue guidance significantly on the strong performance of Tecfidera and the AIFA agreement.
Apple, Microsoft Lead Nasdaq Higher; Dow Falters
at Investor's Business Daily - Wed Jul 23, 10:56AM CDT
Led by Apple (AAPL) and Microsoft (MSFT), the Nasdaq climbed Wednesday, with upside volume perking up for a second straight day. The S&P 500 was trading at a new high, approaching 2000. The Nasdaq rose 0.5%, the S&P 500 gained 0.3% and the Dow Jones...
Video: Biogen Trounces Q2 Estimates On Tecfidera
at Investor's Business Daily - Wed Jul 23, 10:56AM CDT
Big-cap biotech Biogen Idec (BIIB) soundly beat analysts' Q2 expectations and substantially raised its guidance early Wednesday, sending shares up more than 11% in midday trading in the stock market today to near 338, a four-month high. Biogen's Q2...
PLEGRIDY(TM) (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis
Business Wire - Wed Jul 23, 10:41AM CDT
--- Initial Country Launches Expected to Begin in the Coming Weeks -
